Inactive Instrument

Other languages AgeX Therapeutics, Inc.

Equities

AGE

US00848H2076

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	Mar. 25
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22
AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee	Jan. 11
Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023	Dec. 01
Pfizer Signs License Agreement With Serina Therapeutics to Gain Access to POZ Polymer Technology	Nov. 17
AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
AgeX Therapeutics, Inc. Announces Departure of Dr. Michael H. May as Director of the Company	23-09-08
AgeX Therapeutics, Inc. Announces CEO Changes	23-08-14
Agex Therapeutics, Inc. Appoints Jean-Christophe Renondin on the Board of Directors, and Member of Audit Committee, Compensation Committee, and as Chair of the Nominating and Corporate Governance Committee	23-08-14
AgeX Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
AgeX Therapeutics Issues Preferred Shares to Juvenescence in Exchange for Debt Cancellation	23-07-25
AgeX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
AgeX Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30
AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10
AgeX Therapeutics Posts Q2 Loss, Points to Going Concern Issues -- Stock Down 13% After-Hours	22-08-12
AgeX Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q2 Revenue $12,000	22-08-12
AgeX Therapeutics, Inc. Announces Board Changes	22-05-18
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q1 Revenue $5,000	22-05-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages AgeX Therapeutics, Inc.

Equities

AGE

US00848H2076

Other languages

Filters